EPO and chronic kidney disease: For example, sustained erythropoietin treatment may bring side effects (e.g., hypertension and thrombosis) and increase mortality (13), and FGF-23 neutralization failed to mitigate LVH but increased aortic calcification and the risk of mortality in CKD rats (14).